Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1630934 | 0.87 | KEAP1 (0.73) | KEAP1NFE2L2 | |
| SCHEMBL15583923 | 0.87 | MAPT (0.70) | KEAP1NFE2L2 | |
| SCHEMBL1631661 | 0.87 | KEAP1 (0.73) | KEAP1NFE2L2 | |
| SCHEMBL29384986 | 0.87 | KEAP1 (1.00) | KEAP1NFE2L2 | |
| SCHEMBL20723407 | 0.87 | KEAP1 (1.00) | KEAP1NFE2L2 | |
| SCHEMBL7004297 | 0.85 | KEAP1 (0.89) | KEAP1NFE2L2 | |
| SCHEMBL1631188 | 0.84 | KEAP1 (0.69) | KEAP1NFE2L2 | |
| SCHEMBL8710952 | 0.83 | ESR1 (0.60) | KEAP1NFE2L2 | |
| SCHEMBL1629060 | 0.82 | KEAP1 (1.00) | KEAP1NFE2L2 | |
| SCHEMBL798762 | 0.80 | MAPT (0.67) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245006-B1 | SULFONAMIDES AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-06-01 | — | — | EP | disclosed |
| US-7932269-B2 | Sulfonamides as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-7932269-B2 | Sulfonamides as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-7932269-B2 | Sulfonamides as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-04-26 | — | — | US | disclosed |
| WO-2009092642-A1 | SULFONAMIDES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-30 | — | — | WO | disclosed |
| US-20090186920-A1 | SULFONAMIDES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-23 | — | — | US | disclosed |
| US-20090186920-A1 | SULFONAMIDES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-23 | — | — | US | disclosed |
| US-20090186920-A1 | SULFONAMIDES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186920-A1 | SULFONAMIDES AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | KEAP1 1802/4885NFE2L2 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.